论文部分内容阅读
目的探究奥扎格雷钠联合纤溶酶用于脑血栓治疗的临床效果。方法 80例脑血栓患者,随机分为观察组和对照组,各40例。对照组进行常规治疗,观察组在常规治疗基础上给予奥扎格雷钠联合纤溶酶治疗,观察两组患者神经功能缺损改善情况、临床疗效及不良反应发生情况。结果治疗前两组患者美国国立卫生院神经功能缺损评分(NIHSS)量表评分比较差异无统计学意义(P>0.05);治疗后,两组NIHSS评分均较治疗前明显降低,且观察组NIHSS评分明显低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为17.5%,明显低于对照组的40.0%,差异有统计学意义(P<0.05)。观察组治疗总有效率为95.0%,显著高于对照组的75.0%,差异有统计学意义(P<0.05)。结论在脑血栓的临床治疗上,奥扎格雷钠联合纤溶酶的疗效显著,安全性高,值得在临床上推广应用。
Objective To investigate the clinical effect of ozagrel combined with plasmin on cerebral thrombosis. Methods Eighty patients with cerebral thrombosis were randomly divided into observation group and control group, 40 cases in each group. The control group was treated routinely. The observation group was treated with ozagrel sodium combined with plasmin on the basis of routine treatment. The improvement of neurological deficit, clinical curative effect and incidence of adverse reactions were observed in both groups. Results There was no significant difference in NIHSS scores between the two groups before treatment (P> 0.05). After treatment, the NIHSS scores of both groups were significantly lower than those before treatment, and NIHSS The score was significantly lower than the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 17.5%, which was significantly lower than that in the control group (40.0%), the difference was statistically significant (P <0.05). The total effective rate of the observation group was 95.0%, which was significantly higher than that of the control group (75.0%), the difference was statistically significant (P <0.05). Conclusion In the clinical treatment of cerebral thrombosis, ozagrel sodium combined with plasmin has significant curative effect and high safety. It is worth to be popularized clinically.